- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05308719
Nasal Oxygen Therapy After Cardiac Surgery (NOTACS)
Effect of High-Flow Nasal Therapy on Patient-Centered Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients undergoing cardiac surgery are at significant risk of postoperative pulmonary complications that may lead to prolonged ICU and hospital stay and increase mortality. The incidence of respiratory complications may be three to four times more common in patients with intrinsic respiratory disease and lower airway obstruction (including asthma or chronic obstructive pulmonary disease (COPD)), or obese patients or current heavy smokers (> 10 pack years).
High-flow nasal therapy (HFNT) is increasingly used as a non-invasive form of respiratory support. It delivers low level, flow-dependent positive airway pressure, and is much better tolerated by patients than alternatives such as continuous positive airway pressure (CPAP) or non-invasive ventilation. Patients can talk, eat, drink and walk whilst using HFNT. However, there is equipoise regarding its prophylactic use and effect on important patient-centred outcomes. Before the intervention is recommended for routine NHS use in cardiac surgery patients at high risk of pulmonary complications, whether it improves patient-related outcomes and is cost effective in a UK setting needs to be assessed.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Melissa JP Duckworth
- Phone Number: 01223 639667
- Email: Melissa.duckworth@nhs.net
Study Contact Backup
- Name: Ellen B Temple, MBiol
- Phone Number: 01223 639809
- Email: ellen.temple4@nhs.net
Study Locations
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, United Kingdom, CB20AY
- Recruiting
- Royal Papworth Hospital NHS Foundation Trust
-
Contact:
- Melissa JP Duckworth
- Phone Number: 01223 639667
- Email: Melissa.duckworth@nhs.net
-
Contact:
- Ellen B Temple, MBiol
- Phone Number: 01223 639809
- Email: ellen.temple4@nhs.net
-
Principal Investigator:
- Andrew Klein, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 years or over.
- Undergoing any elective or urgent first-time or redo cardiac surgery performed on cardiopulmonary bypass
- Have one or more clinical risk factors for postoperative pulmonary complications (COPD, asthma, lower respiratory tract infection in last 4 weeks as defined by use of antibiotics, body mass index ≥35 kg/m2 , current (within the last 6 weeks) heavy smoker (> 10 pack years)) (47, 48).
Asthma is a disease characterized by recurrent attacks of breathlessness and wheezing, and patients will have been prescribed medication by inhalers or nebulisers (either bronchodilators or steroids).
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow. The more familiar terms 'chronic bronchitis' and 'emphysema' are no longer used but are now included within the COPD 13 diagnosis. The most common symptoms of COPD are breathlessness, or a 'need for air', excessive sputum production, and a chronic cough. Patients suitable for the NOTACS study will have been prescribed medication by inhalers or nebulisers (either bronchodilators or steroids).
Exclusion Criteria:
- Requiring home oxygen therapy.
- Deep hypothermic circulatory arrest planned
- Contraindication to HFNT, e.g. nasal septal defect.
- Requirement for home ventilatory support (including: HFNT, CPAP, BiPAP)
- Requiring emergency cardiac surgery defined as surgery required within 24 hours of the decision to operate.
- Patients not fluent in English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard Oxygen Therapy
Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation.
Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter.
If saturations < 93% then FiO2 will be increased as per respiratory escalation protocol.
Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
|
|
Other: High-Flow Nasal Therapy
High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min.
Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter.
If saturations < 93% then increase FiO2 as per respiratory escalation protocol.
High flow nasal therapy will be given for a minimum of 16 hours post extubation.
|
High Flow Nasal Oxygen (Airvo2 Device)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days alive and at home in the first 90 days after surgery, for adult patients undergoing cardiac surgery who are at high risk of postoperative pulmonary complications who either receive High flow nasal therapy or Standard oxygen therapy
Time Frame: 90 days
|
Number of days at home in the first 90 days after surgery, measured by the patient facing Patient Location and Medication Diary at 90 days
|
90 days
|
Incremental cost-effectiveness and cost-utility of High flow nasal therapy versus Standard therapy for patients undergoing cardiac surgery who are at high risk of postoperative pulmonary complications at 90 days
Time Frame: 90 days
|
Health Economic analysis to estimate the incremental cost-effectiveness and cost-utility of High flow nasal therapy versus Standard therapy at 90 days from the view point of the public sector, NHS and patient, measured by using Patient and Family Resource Use patient facing Questionnaires at 90 days.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimates of the incremental cost-effectiveness and cost-utility of High flow nasal therapy versus standard oxygen therapy for adult patients undergoing cardiac surgery who are at high risk of postoperative pulmonary complications at 30 days.
Time Frame: 30 days
|
Health Economic analysis to estimate the incremental cost-effectiveness and cost-utility of High flow nasal therapy versus Standard therapy at 90 days from the view point of the public sector, NHS and patient, measured by using Patient and Family Resource Use patient facing Questionnaires at 30 days.
|
30 days
|
Incidence of mortality, pulmonary complications, intensive care re-admission rate, length of hospital and intensive care stay .
Time Frame: Discharge on average 7 days post operation, 30 and 90 days
|
Mortality measured by the incidence of death reported from patient follow-up and medical records at 30 and 90 days. Incidence of postoperative pulmonary complications measured using medical notes during primary admission to hospital. ICU re-admission rate measured using the in-patient diary eCRF at any time during primary hospital admission Length of ICU stay (days) measured using the in-patient diary eCRF during primary hospital admission Length of hospital stay (days) measured using the in-patient diary eCRF during primary hospital admission |
Discharge on average 7 days post operation, 30 and 90 days
|
Incidence of major complications including sepsis, renal failure, myocardial infarction and stroke.
Time Frame: 30 and 90 days
|
Incidence of stroke measured from patient follow-up and medical records at 30 and 90 days Incidence of sepsis measured from patient follow-up and medical records at 30 and 90 days Incidence of myocardial infarction measured from patient follow-up and medical records at 30 and 90 days
|
30 and 90 days
|
Incidence of readmission to hospital rate.
Time Frame: 90 days
|
Incidence of readmission to hospital rate, measured using the in-patient diary eCRF during primary hospital admission and patient location and medication diary for patient completion up to 90 days
|
90 days
|
Statistical analysis of oxygenation as measured by the ROX Index (as defined as Sp02/Fi02 to respiratory rate ratio).
Time Frame: 2,6,12,24,and 48 hours post extubation
|
Oxygenation measured by ROX Index (defined as Sp0₂/Fi0₂ to respiratory rate ratio) at 2, 6, 12, 24 and 48 hours post-extubation
|
2,6,12,24,and 48 hours post extubation
|
Statistical analysis of patient-centered outcomes as measured using the EQ-5D-5L Quality of Survival
Time Frame: Discharge on average 7 days post operation, 30 and 90 days
|
Quality of Survival will be as measured using ED-5D-5L Quality adjusted life years (QALYs).
|
Discharge on average 7 days post operation, 30 and 90 days
|
Statistical Analysis to determine if prophylactic use of high- flow nasal oxygen reduces health service and resource use.
Time Frame: Discharge on average 7 days post operation, 30 and 90 days
|
Health service and resource use measured using Patient and Family Resource Use Questionnaires at baseline, discharge, 30 and 90 days
|
Discharge on average 7 days post operation, 30 and 90 days
|
Statistical analysis of patient level of assistance needed with activities of daily living post surgery as measured using BARTHEL questionnaire.
Time Frame: Discharge on average 7 days post operation, 30 and 90 days
|
Patient level of assistance needed with activities of daily living, measured using the BARTHEL questionnaire at baseline, discharge, 30 and 90 day
|
Discharge on average 7 days post operation, 30 and 90 days
|
Statistical analysis of patient-centered outcomes as measured using the EQ-5D-5L
Time Frame: Discharge on average 7 days post operation, 30 and 90 days
|
Patient-reported outcomes measured using the EQ-5D-5L questionnaire at baseline, discharge, 30 and 90 days 12. Quality of Survival will be as measured using ED-5D-5L Quality adjusted life years (QALYs).
|
Discharge on average 7 days post operation, 30 and 90 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrew Klein, Royal Papworth Hospital NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P02590
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on High Flow Nasal Therapy
-
Henrik EndemanFranciscus Gasthuis; Maasstad HospitalRecruitingRespiratory Failure | Post Extubation Acute Respiratory Failure Requiring ReintubationNetherlands
-
Hamad Medical CorporationRecruitingHigh-flow Nasal Oxygen Therapy to Prevent Extubation Failure in Adult Trauma Intensive Care PatientsAirway Extubation | Critical Care | Intensive Care | Oxygen TherapyQatar
-
Osaka UniversityOsaka City General Hospital; Osaka Women's and Children's Hospital; Hyogo Prefectural... and other collaboratorsRecruitingPediatric Patients After Cardiothoracic SurgeryJapan
-
Papworth Hospital NHS Foundation TrustCompleted
-
Maha Mahmoud AhmedNot yet recruitingHigh Flow Nasal Therapy
-
Maastricht Radiation OncologyCompletedBreast Cancer | Lung CancerNetherlands
-
National Hospital Organization Minami Kyoto HospitalCompletedRehabilitation | Chronic Respiratory Failure | Exercise Endurance | Nasal High Flow TherapyJapan
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownRespiratory InsufficiencyChina
-
University Medical Center GroningenTerminatedCheyne-Stokes Respiration | Central Sleep ApneaNetherlands
-
Hôpital de VerdunNot yet recruitingHypercapnic Respiratory Failure | Acute Copd ExacerbationCanada